Novartis failed to convince a U.S. appeals court on Wednesday to halt MSN Pharmaceuticals' proposed generic of Novartis' ...
Comparison measures of lung function and improved categorization of cardiovascular disease (CVD) risk were among the key ...
Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce the three recipients of its inaugural Health Equity ...
The U.S. Court of Appeals has reportedly ruled against Novartis (NVS) in its bid to prevent the U.S. launch of a generic ...
Shares of Divi's Laboratories Ltd. are down by up to 6% on Thursday, December 5, following Novartis losing its appeal in a US ...
HSBC analyst Rajesh Kumar downgraded Novartis (NVS) to Reduce from Hold with a price target of CHF 82, down from CHF 95. The firm calls the ...
Divi's Laboratories Ltd's shares were trading nearly 3% lower on December 5 as Novartis failed to persuade a US appeals court on Wednesday to halt MSN Pharmaceuticals' proposed generic of Novartis' ...
Switzerland-based Novartis has one of the strongest and broadest portfolios of varied drugs that has enabled it to maintain its dominant position as a top pharma company over the years. It continues ...
Monte Rosa Therapeutics stock surged after a recent partnership with Novartis, despite limited clinical results. Can the ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
In my talks on innovation and simplification, I pose a simple question to my audiences: "How many of you wish you had more ...
The U.S. Food and Drug Administration has approved Merus NV's therapy that targets a particular gene, expanding treatment ...